Log in to search using one of your social media accounts:

 

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation
• Expanding a portion of a UCB unit in cytokines with tetraethylenepentamine led to a median 77 fold expansion of CD34+ cells• Compared to a contemporaneous double UCB cohort, transplantation of expanded and remaining unexpanded cells led to a lower 100 day mortality• Faster neutrophil and pla telet engraftment was also seen also for the group transplanted with the expanded cells (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 22, 2018 Category: Hematology Authors: Patrick J. Stiff, Pau Montesinos, Tony Peled, Efrat Landau, Noga Rosenheimer Goudsmid, Julie Mandel, Nira Hasson, Esti Olesinski, Ela Glukhman, David A. Snyder, Einat Galamidi Cohen, Orna Srur Kidron, Dalia Bracha, Dorit Harati, Keren Ben-Abu, Etty Freind Source Type: research

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukaemia: a Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party and the Acute Leukaemia Working Party of the EBMT
This study aimed to evaluate which W-CBU factors can predict unit dominance and how they influence DUCBT outcomes in patients with acute leukaemia• No W-CBU factors were associated with unit dominance• DUCBT outcomes were negatively influenced by higher degree of HLA mismatch between W-CBU a nd recipient• Selecting both units based on lower degree of HLA mismatch along with other standard selection criteria is indicated (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 22, 2018 Category: Hematology Authors: Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, Annalisa Ruggeri, Fernanda Volt, Annalisa Paviglianiti, Chantal Kenzey, Hiromi Hayashi, Jan Cornelissen, Mauricette Michallet, Dimitrios Karakasis, Eric Deconinck, Pierre-Simon Rohrlich, Regis Peffa Source Type: research

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: a Single Center Experience Study
• Defibrotide seems effective in preventing sinusoidal obstruction syndrome.• This prophylaxis is associated with an acceptable bleeding events incidence.• Defibrotide prophylaxis might reduce the incidence of other early complications. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 22, 2018 Category: Hematology Authors: Adrien Picod, Agn ès Bonnin, Giorgia Battipaglia, Federica Giannotti, Annalisa Ruggeri, Eolia Brissot, Florent Malard, Clémence Médiavilla, Ramdane Belhocine, Anne Vekhoff, Mor Sény Gueye, Simona Lapusan, Rosa Adaeva, Françoise Isnard, Ollivier Legra Source Type: research

Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success
• We developed a new endpoint, refractory graft-versus-host disease-free, relapse-free survival (rGRFS).• We validated current GRFS (cGRFS) using two distinct methods.• cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS.• The curves of cGRFS and rGRFS overlappe d after the first two years of post-transplant follow-up.• rGRFS can be easily calculated and analyzed with widely-used statistical approaches. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 21, 2018 Category: Hematology Authors: Koji Kawamura, Hideki Nakasone, Saiko Kurosawa, Kazuki Yoshimura, Yukiko Misaki, Ayumi Gomyo, Jin Hayakawa, Masaharu Tamaki, Yu Akahoshi, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Yuko Ishihara, Miki Sato, Kiriko Terasako-Saito, Misato Kikuchi, Shun- Source Type: research

Design and Patient Characteristics of the Chronic Graft-Versus-Host Disease Response Measures Validation Study
In 2014, the National Institutes of Health sponsored the second Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-vs-Host (GVHD). The purpose was to update recommendations about key elements of chronic GVHD research, including definitions for diagnosis, severity scoring, and response measures, based on empirical data published since the first 2005 Consensus Conference. The most significant modifications were to the response assessments, since studies demonstrated difficulty with the first consensus definitions. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 21, 2018 Category: Hematology Authors: Stephanie J. Lee, Betty K. Hamilton, Joseph Pidala, Amin Alousi, Chareeni Kurukulasuriya, Lynn Onstad, Madan Jagasia, George Chen, Corey Cutler, Raewyn Brody, Mukta Arora, Sally Arai, Stefanie Sarantopoulos, Mary E. Flowers Source Type: research

Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities
• We assessed the clinical impact of HCT-CI in umbilical cord blood transplantation.• Umbilical cord blood (UCB) transplantation showed good OS despite the high HCT-CI.• Single-unit UCB is a promising stem cell source for patients with comorbidities. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 21, 2018 Category: Hematology Authors: Yoshitaka Adachi, Shun Ukai, Ken Sagou, Nobuaki Fukushima, Kazutaka Ozeki, Akio Kohno Source Type: research

Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate Into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes: a Single Center Experience
• Improving IPSS-R before transplant did not translate into better survival outcome.• Blast count pre-transplant was highly predictive of post-transplant outcome.• Survival outcome was affected by cytogenetic at diagnosis and the status of cGVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 20, 2018 Category: Hematology Authors: Musa Alzahrani, Maryse Power, Yasser Abou Mourad, Michael Barnett, Raewyn Broady, Donna Forrest, Alina Gerrie, Donna Hogge, Stephen Nantel, David Sanford, Kevin Song, Heather Sutherland, Cynthia Toze, Thomas Nevill, Sujaatha Narayanan Source Type: research

In the Era of BCR-ABL1 Inhibitors, are We Closing the Survival Gap between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Ph+ ALL in First Complete Remission?
Commentary on “Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia” by Wang J, et al. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 20, 2018 Category: Hematology Authors: Matthew J. Wieduwilt Source Type: research

Microbiome-Host Interactions in Hematopoietic Stem-Cell Transplant Recipients
• Microbiome alterations are associated with infection, GVHD, and other adverse transplant outcomes.• “Multi-omic” technologies may better identify clinically actionable microbiome biomarkers.• Functional microbial characterization may improve diagnostic and therapeutic strategies.• Know ledge gaps persist in chronic GVHD and extra-intestinal microbiome-host interactions.• Multi-institutional studies and data collection expansion will maximize microbiome research impact. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 19, 2018 Category: Hematology Authors: Tessa Andermann, Jonathan Peled, Christine Ho, Pavan Reddy, Marcie Riches, Rainer Storb, Takanori Teshima, Marcel van den Brink, Amin Alousi, Sophia Balderman, Patrizia Chiusolo, William Clark, Ernst Holler, Alan Howard, Leslie Kean, Andrew Koh, Philip Mc Source Type: research

Effects of Prophylactic Foscarnet on HHV-6 Reactivation and HHV-6 Encephalitis in Cord Blood Transplant Recipients: a Prospective Multicenter Trial with a Historical Control Group
• Prospective, multicenter trial of foscarnet prophylaxis against HHV-6 reactivation.• HHV-6 reactivation incidence was lower with foscarnet than in historical controls.• Foscarnet did not prevent HHV-6 encephalitis or acute GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 15, 2018 Category: Hematology Authors: Masao Ogata, Kuniko Takano, Yukiyoshi Moriuchi, Tadakazu Kondo, Toshimitsu Ueki, Nobuaki Nakano, Takehiko Mori, Nobuhiko Uoshima, Koji Nagafuji, Satoshi Yamasaki, Yasuhiko Shibasaki, Rika Sakai, Koji Kato, Ilseung Choi, Yumi Jo, Tetsuya Eto, Shinichi Kako Source Type: research

Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most
• Younger age is associated with better survival after HLA-matched unrelated hemopoietic cell transplant• Other donor characteristics tested were not consistently associated with survival• In the HLA-matched setting the youngest donor should be prioritized (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 15, 2018 Category: Hematology Authors: Bronwen E. Shaw, Brent R. Logan, Stephen R. Spellman, Steven G.E. Marsh, James Robinson, Joseph Pidala, Carolyn Hurley, Juliet Barker, Martin Maiers, Jason Dehn, Hailin Wang, Mike Haagenson, David Porter, Effie W. Petersdorf, Ann Woolfrey, Mary M. Horowit Source Type: research

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors
• With post-transplant cyclophosphamide, haploidentical BMT from non-first-degree relatives has similar results to first-degree relatives.• Non-first degree relatives (e.g., aunts, uncles, cousins, nieces, nephews and grandchildren) should be considered for BMT donor searches.• Future studies should focus on assessing donor selection strategies and optimizing relapse rates. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 13, 2018 Category: Hematology Authors: Hany Elmariah, Yvette L. Kasamon, Marianna Zahurak, Karen W. Macfarlane, Noah Tucker, Gary L. Rosner, Javier Bola ños-Meade, Ephraim J. Fuchs, Nina Wagner-Johnston, Lode J. Swinnen, Carol Ann Huff, William H. Matsui, Douglas E. Gladstone, Shannon R. McCu Source Type: research

HLA-Matched Sibling Vs. Unrelated Vs. Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: a Single-Center Donor Comparison
• Haploidentical stem cell transplantation (Haplo-SCT) is feasible in patients ≥ 60 years with acute myeloid leukemia• Unrelated donor (UD) transplantation is associated with higher incidence of acute GVHD in elderly patients• Haplo-SCT is a valuable alternative to UD in absence of matched s ibling donor (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 12, 2018 Category: Hematology Authors: Raynier Devillier, Faezeh Legrand, J érôme Rey, Luca Castagna, Sabine Fürst, Angela Granata, Aude Charbonnier, Samia Harbi, Evelyne d'Incan, Thomas Pagliardini, Catherine Faucher, Claude Lemarie, Colombe Saillard, Boris Calmels, Bilal Mohty, Valerio Ma Source Type: research

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
We studied if the inclusion of early post stem cell transplant (SCT) minimal residual disease (MRD) assessments improved prognostication in patients with acute myeloid leukemia (AML). Two-hundred sixty-nine AML patients in morphological complete remission (CR) who underwent a first SCT were included if they had evaluable pre-SCT MRD assessment by multiparametric flow cytometry. Post-SCT MRD assessments were performed at Days +30, +100, and +180. The primary outcome was 1-year relapse incidence (RI). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 12, 2018 Category: Hematology Authors: Mithun Vinod Shah, Jeffrey L. Jorgensen, Rima M. Saliba, Sa A. Wang, Amin M. Alousi, Borje S. Andersson, Qaiser Bashir, Stefan O. Ciurea, Partow Kebriaei, David Marin, Keyur P. Patel, Uday R. Popat, Katy Rezvani, Gabriela Rondon, Elizabeth J. Shpall, Rich Source Type: research

Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients
• Higher MPA acyl glucuronide concentrations were related with aGVHD of the GI tract.• Free MPA concentrations were associated with faster neutrophil engraftment.• Therapeutic range was suggested as free MPA AUC0-24 of 0.405–0.689 µg⋅h⋅mL−1. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 7, 2018 Category: Hematology Authors: Kazuaki Yoshimura, Ikuko Yano, Takashi Yamamoto, Tadakazu Kondo, Misaki Kawanishi, Yui Isomoto, Atsushi Yonezawa, Akifumi Takaori-Kondo, Kazuo Matsubara Source Type: research

A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: a Multicenter Study
• A favourable use of Baltimore protocol for Haplo bone marrow transplant is described.• It is associated to a very low rate of relapse in remission patients.• We have seen a low incidence of GvHD, despite the use of cyclosporine before PT-CY.• These results may not translate automatically t o unmanipulated peripheral blood. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2018 Category: Hematology Authors: Patrizia Chiusolo, Gesine Bug, Attilio Olivieri, Mats Brune, Nicola Mordini, Paolo Emilio Alessandrino, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Francesca Gualandi, Maria Teresa Van Lint, Felicetto Ferrara, Olimpia Finizio, Emanuele Angelucc Source Type: research

Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant
• Stem cell transplant (SCT) recipients are at high risk for cervical dysplasia, and cervical cancer screening is recommended. However, screening rates and timing after stem cell transplant (SCT) is not clear.• Using a large commercial claims database, we found that that the screening rates was low, 44.5%, within 2 years after allogeneic or autologous SCT.• Younger age, a diagnosis of leukemia, and not having graft-versus-host disease or comorbid medical conditions were predictors of cervical cancer screening. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 4, 2018 Category: Hematology Authors: Jessica P. Hwang, Sairah Ahmed, Ella J. Ariza-Heredia, Zhigang Duan, Hui Zhao, Kathleen M. Schmeler, Lois Ramondetta, Susan L. Parker, Maria E. Suarez-Almazor, Alessandra Ferrajoli, Ya-Chen Tina Shih, Sharon H. Giordano, Elizabeth Y. Chiao Source Type: research

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy
• Black patients have improved survival following haploidentical transplantation.• This benefit was due to a lower incidence of relapse/progression in black patients.• A higher rate of mild chronic GVHD in black patients may be a contributing factor. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 4, 2018 Category: Hematology Authors: Scott R. Solomon, Xu Zhang, H. Kent Holland, Lawrence E. Morris, Melhem Solh, Asad Bashey Source Type: research

Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis, Type I (Hurler Syndrome)
• Metabolic syndrome is uncommon after hematopoietic cell transplantation in severe MPS I• High blood pressure is the most common metabolic syndrome component in long term survivors (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 4, 2018 Category: Hematology Authors: Elizabeth Braunlin, Julia Steinberger, Todd DeFor, Paul Orchard, Aaron S. Kelly Source Type: research

Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. gallinarum and E. casseliflavus) and Outcomes of Allogeneic Hematopoietic Cell Transplantation
Gut colonization with vancomycin-resistant enterococci (VRE) —Enterococcus faecium and Enterococcus faecalis—is common. Approximately 15% to 40% of patients are VRE colonized before allogeneic hematopoietic cell transplantation (allo-HCT) and an additional ~10% become colonized within the first 100 days post-HCT [1-3]. We and others have shown that VRE co lonization is associated with>3-fold increased risk of post-HCT VRE bloodstream infection [1,2,4] with an attributable mortality rate of ~10% [2,3,5,6]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Armin Rashidi, Maryam Ebadi, Robin R. Shields-Cutler, Todd E. DeFor, Gabriel A. Al-Ghalith, Patricia Ferrieri, Jo-Anne H. Young, Gary M. Dunny, Dan Knights, Daniel J. Weisdorf Source Type: research

Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial
β-Thalassemia is caused by mutations that reduce or abrogate β-globin synthesis. The accumulation of excess α-globin tetramers precipitate and trigger ineffective erythropoiesis [1]. Patients with homozygous or compound heterozygous hemoglobin subunit beta null mutations develop severe anemia ear ly in life and require lifelong regular RBC transfusions (transfusion-dependent thalassemia [TDT]) and iron chelation therapy to prevent organ toxicity from accumulated iron [2]. This cumbersome and expensive medical therapy and the associated risks of iron overload and organ toxicity have stimulate d investigation...
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Shalini Shenoy, Mark C. Walters, Alex Ngwube, Sandeep Soni, David Jacobsohn, Sonali Chaudhury, Michael Grimley, Kawah Chan, Ann Haight, Kimberley A. Kasow, Suhag Parikh, Martin Andreansky, Jim Connelly, David Delgado, Kamar Godder, Gregory Hale, Michael N Source Type: research

Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the URTH Trial
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial, we investigated the efficacy of reduced intensity conditioning (RIC) before unrelated donor (URD) HSCT in children with TDT. Thirty-three children (1-17 years), received marrow or cord blood (UCB) allografts. Median time to neutrophil engraftment was 13 (range, 10-25) and 24 (range, 18-49) days; platelet engraftment was 23 (range, 12-46) and 50 (range, 31-234) days after marrow and UCB respectively. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Shalini Shenoy, Mark C. Walters, Alex Ngwube, Sandeep Soni, David Jacobsohn, Sonali Chaudhury, Michael Grimley, Kawah Chan, Ann Haight, Kimberley A. Kasow, Suhag Parikh, Martin Andreansky, Jim Connelly, David Delgado, Kamar Godder, Gregory Hale, Michael N Source Type: research

Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: a Systematic Review and Meta-Analysis
• A meta-analysis comparing autologous HSCT to immunosuppression in system sclerosis• Transplantation is associated with a reduction in overall mortality• Transplantation is associated with an improvement in skin thickness, lung function, and quality of life• Autologous SCT is a Disease-Modi fying Anti-Rheumatic Treatment for systemic sclerosis (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Roni Shouval, Nadav Furie, Pia Raanani, Arnon Nagler, Anat Gafter-Gvili Source Type: research

Pre-Transplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. Gallinarum and E. Casseliflavus) and Outcomes of Allogeneic Hematopoietic Cell Transplantation
• Pre-transplant iVRE gut colonization is uncommon and with unknown clinical impact.• OS was higher among patients with vs. without pre-transplant iVRE gut colonization.• Putative metabolomes differentiated iVRE from E. faecalis/faecium.• Unique iVRE metabolomes may create a healthier gut mi crobiome in colonized patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Armin Rashidi, Maryam Ebadi, Robin R. Shields-Cutler, Todd E. DeFor, Gabriel A. Al-Ghalith, Patricia Ferrieri, Jo-Anne H. Young, Gary M. Dunny, Dan Knights, Daniel J. Weisdorf Source Type: research

The Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: a Nation-Wide Survey in Japan
• The efficacy and long-term outcomes of autologous stem cell transplantation (ASCT) in 95 POEMS patients in Japan were investigated.• This is a nationwide multicenter retrospective study assessing the clinical course of patients registered to the Japan Society for Hematopoietic Cell Transplanta tion TRUMP database.• ASCT has dramatically improved patients' ADL.• Over a median follow-up of 46.6 months, 5-year overall survival was 88.8%, and 3-year progression-free survival was 78.3%.• ASCT are promising for both improving QoL and prolonging survival in patients with POEMS syndrome. (Source: Biology...
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Chika Kawajiri-Manako, Emiko Sakaida, Chikako Ohwada, Toshihiro Miyamoto, Taichi Azuma, Jun Taguchi, Takehiko Mori, Yuichi Hasegawa, Tadakazu Kondo, Toshiaki Yujiri, Makoto Yoshimitsu, Kazunori Imada, Shingo Kurahashi, Kaoru Kahata, Tatsuo Ichinohe, Makot Source Type: research

Inflammation-Associated Cytokines IGFBP1 and RANTES Impair the Megakaryocytic Potential of HSCs in PT Patients after Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a pivotal therapy for an increasing variety of malignant and non-malignant hematologic disorders[1]. Platelet reconstitution is a key measurement of successful engraftment after HSCT. However, prolonged isolated thrombocytopenia (PT), a frequent complication in patients after allo-HSCT, occurs in 5 –37% of HSCT recipients[3,4,5] . The diagnosis of PT is made when a decrease in platelet number ( (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Cuicui Liu, Yiqing Yang, Dan Wu, Wenxia Zhang, Hongtao Wang, Pei Su, Jianfeng Yao, Chen Liang, Sizhou Feng, Mingzhe Han, Fuxu Wang, Erlie Jiang, Jiaxi Zhou Source Type: research

“Diagnostic Utility of Endoscopy and Biopsy in Suspected Acute Gastrointestinal Graft Versus Host Disease (GI-GVHD) Following Haematopoietic Progenitor Cell Transplantation (HPCT).”
• Routine performance of upper endoscopy does not significantly increase diagnostic yield for GI-GVHD.• Diarrhoea and advanced age are the only predictors for identifying histological GVHD in patients suspected of having GI-GVHD.• Of the patients who are ultimately treated for GI-GVHD, only 74 % have GVHD confirmed on biopsy, thus highlighting a need for improved diagnostic techniques. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Ashleigh Scott, Siok-Keen Tey, Jason Butler, Glen A. Kennedy Source Type: research

Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
• Carfilzomib(K) can be safely combined with MEL200 as auto-HCT preparative regimen.• K-MEL auto-HCT yields promising efficacy in patients with relapsed MM.• Carfilzomib is well tolerated maintenance after salvage auto-HCT in MM. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Luciano J. Costa, Heather J. Landau, Saurabh Chhabra, Parameswaran Hari, Racquel Innis-Shelton, Kelly N. Godby, Mehdi Hamadani, Roni Tamari, Kate Anderton, Pamela Dixon, Sergio A. Giralt Source Type: research

Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection
• Optimal unrelated donor selection has the potential to improve HCT success• We developed a multi-variable machine learning algorithm to improve donor selection• Despite promising preliminary results, the algorithm failed in pivotal study• Translating machine learning risk predictors to cli nical use is a major challenge (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Ljubomir Buturovic, Jason Shelton, Stephen R. Spellman, Tao Wang, Lyssa Friedman, David Loftus, Lyndal Hesterberg, Todd Woodring, Katharina Fleischhauer, Katharine C. Hsu, Michael R. Verneris, Mike Haagenson, Stephanie J. Lee Source Type: research

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report
• Addition of plerixafor to G-CSF did not affect clinical or LT safety outcomes• No differences were noted in 5 year OS/PFS for plerixafor treated patients• No difference in composite endpoint of death, progression, or additional treatment (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Ivana N. Micallef, Patrick J. Stiff, Auayporn P. Nademanee, Richard T. Maziarz, Mitchell E. Horwitz, Edward A. Stadtmauer, Jonathan L. Kaufman, John M. McCarty, Rita Vargo, Peter D. Cheverton, Martin Struijs, Brian Bolwell, John F. DiPersio Source Type: research

Addressing Ethical and Procedural Principles for Unrelated Allogeneic Hematopoietic Progenitor Cell Donation in a Changing Medical EnvironmentBScomment >
Since its establishment, the World Marrow Donor Association (WMDA) has developed standards in line with published international guidelines and policies to ensure the safety of adult volunteer donors and quality of hematopoietic progenitor cell (HPC) products [1]. The requirements for (written) informed consent at time of the various stages from recruitment to donation are described in the WMDA Standards [2]. Recruitment, high-resolution HLA typing, verification typing, and work-up for donation of standard cell products (bone marrow or peripheral blood stem cell [PBSC] donation or subsequent donation, including therapeutic ...
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Suzanna M. van Walraven, Torstein Egeland, Veronica Borrill, Grazia Nicoloso-de Faveri, Gabi Rall, Jeff Szer, Working Group Medical of the World Marrow Donor Association Source Type: research

Single Antigen –Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors
Remarkable advances in the treatment of most hematologic malignancies have been seen in recent years, particularly regarding the emerging biologic targeted therapies. Nevertheless, allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only potentially curative treatment for many of them. Historically, donor –recipient HLA compatibility was identified as the leading factor in predicting the outcome of alloHSCT, with multiple studies reporting worse overall outcomes associated with increasing degrees of HLA mismatch, particularly because of higher rates of graft-versus-host-disease (GVHD), graft fai...
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Ana Sofia Jorge, Mar ía Suárez-Lledó, Arturo Pereira, Gonzalo Gutierrez, Francesc Fernández-Avilés, Laura Rosiñol, Noemí Llobet, Teresa Solano, Álvaro Urbano-Ispízua, Montserrat Rovira, Carmen Martínez Source Type: research

Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation
1. Using a multi-institutional retrospective database we looked at the outcomes of patients who relapsed following allogeneic hematopoietic cell transplantation (allo-HCT).2. Median post relapse overall survival was longer in patients with Hodgkin lymphoma compared to indolent and aggressive non-Hodgkin lymphoma.3. Patients who relapsed late, had good performance status and who were able to receive salvage therapy had significantly reduced risk of mortality.4. In the contemporaneous era, therapies used for patients experiencing post allo-HCT lymphoma relapse can extend survival. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Narendranath Epperla, Mehdi Hamadani, Kwang W. Ahn, Fiona He, Dheeraj Kodali, Ariel Kleman, Parameswaran N. Hari, Marcelo Pasquini, Timothy S. Fenske, Michael D. Craig, Abraham S. Kanate, Veronika Bachanova Source Type: research

Addressing Ethical and Procedural Principles for Unrelated Allogeneic Haematopoietic Progenitor Cell Donation in a Changing Medical Environment.
Transplantation of allogeneic haematopoietic progenitor cells (HPC), as part of a potential life-saving treatment for haematological disorders, is a well-established medical procedure. Due to the efforts of the World Marrow Donor Association (WMDA) and other professional medical and scientific organisations, donation and collection of HPC from adult volunteer donors has become suitably regulated and standardized. Ongoing changes in the treatment of haematological disorders however, have led to a practice where organisations providing HPC from volunteer donors are confronted with requests for multiple or other than standard...
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: S.M. van Walraven, T. Egeland, V. Borrill, G. Nicoloso-de Faveri, G. Rall, J. Szer, Working Group Medical of the World Marrow Donor Association Source Type: research

Single-Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide is a Suitable Alternative for Patients Lacking HLA-Matched Donors
• Single-antigen MMUD transplants using PTCy has similar survival outcomes that MUD transplants.• PTCyMMUD seems to be associated to low rates of moderate/severe chronic GVHD.• This platform may expand the donor pool for patients who lack a matched related or unrelated donor. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Ana Sofia Jorge, Mar ía Suárez-Lledó, Arturo Pereira, Gonzalo Gutierrez, Francesc Fernández-Avilés, Laura Rosiñol, Noemí Llobet, Teresa Solano, Álvaro Urbano-Ispízua, Montserrat Rovira, Carmen Martínez Source Type: research

Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy
• Active HLH disease at time of HSCT does not preclude successful patient outcome;• Treosulfan-based regimens resulted in low TRM and rate of graft failure;• HLA-mismatched HSCT was associated with reduced rate of engraftment;• Rejection/secondary graft failure are events that could be salva ged by a 2nd HSCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Chiara Messina, Marco Zecca, Franca Fagioli, Attilio Rovelli, Stefano Giardino, Pietro Merli, Fulvio Porta, Maurizio Aric ò, Elena Sieni, Giuseppe Basso, Mimmo Ripaldi, Claudio Favre, Marta Pillon, Antonio Marzollo, Marco Rabusin, Simone Cesaro, Mattia A Source Type: research

Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation
• Patient engagement is critical to inform patient-centered outcomes research (PCOR)• Multiple methods exist to engage patients in research and should be tailored to fit their preferences• PCOR recommendations in HCT by six Working Groups are presented (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Linda J. Burns, Beatrice Abbetti, Stacie D. Arnold, Jeffrey Bender, Susan Doughtie, Areej El-Jawahiri, Gloria Gee, Theresa Hahn, Mary M. Horowitz, Shirley Johnson, Mark Juckett, Lakshmanan Krishnamurit, Susan Kullberg, C. Fred LeMaistre, Alison Loren, Nav Source Type: research

Allogeneic Hematopoietic Stem-Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen
• Multiple phenotypes of disease complicate the choice of conditioning for stem cell transplantation in GATA2 deficiency.• Reduced intensity has been insufficient for engraftment or prevention of relapse of hematologic disorders or cytogenetic abnormalities.• A busulfan-based regimen targeted an AUC betwen 3600 and 4800 µMol*min and added post-transplant high dose cyclophosphamide for graft-versus-host disease prophylaxis in recipients from haploidentical donors.• Engraftment was achieved in all recipients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Mark Parta, Nirali N. Shah, Kristin Baird, Hind Rafei, Katherine R. Calvo, Thomas Hughes, Kristen Cole, Meg Kenyon, Bazetta Blacklock Schuver, Jennifer Cuellar-Rodriguez, Christa S. Zerbe, Steven M. Holland, Dennis D. Hickstein Source Type: research

Low CD34+ Cell Doses are Associated with Increased Cost and Worse Outcome Following of Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors
• 23% of GCT patients collect a suboptimal number of PBSC for tandem ASCT using filgrastim• Low CD34+ cell doses are associated increased transplant costs and worse survival• Despite higher costs and worse outcome, low CD34 cell doses should not preclude ASCT (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Mustafa A. Hyder, W. Scott Goebel, Kirsten D. Ervin, Jennifer E. Schwartz, Michael J. Robertson, Teresa C. Thakrar, Costantine Albany, Sherif S. Farag Source Type: research

Donor Cell-Derived Hematological Neoplasms after Hematopoietic Stem Cell Transplantation. a Systematic Review.
• Leukemic transformation of donor hematopoietic stem cells provides a useful model to study the mechanisms involved in leukemogenesis.• A systematic analysis of 137 cases reported in the literature highlights several factors that may contribute to the development of donor cell derived hematolog ical neoplasms after allo-SCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Julia Su árez-González, Carolina Martínez-Laperche, Mi Kwon, Pascual Balsalobre, Diego Carbonell, María Chicano, Gabriela Rodríguez-Macías, David Serrano, Jorge Gayoso, José Luis Díez-Martín, Ismael Buño Source Type: research

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
• A third ASCT may be an option for relapsed myeloma patients• If relapse ≥ 36 months after a tandem ASCT, median PFS was 24 months and OS 64 months• Toxicity after a third ASCT was acceptable• Progressive disease and Karnofsky score (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Laurent Garderet, Simona Iacobelli, Linda Koster, Hartmut Goldschmidt, Jan-Erik Johansson, Jean Henri Bourhis, Marta Krejci, Xavier Leleu, Michael Potter, Didier Blaise, Christian Koenecke, Christian Peschel, Jakub Radocha, Bernd Metzner, Pascal Lenain, K Source Type: research

Higher Donor Apheresis Blood Volumes are Associated with a Reduction in Relapse Risk and Improved Survival in Reduced Intensity Allogeneic Transplants with Unrelated Donors
• Donor apheresis volume ≥ 15L is associated with better survival after transplant.• The survival advantage is driven by a decrease in relapse risk.• Higher apheresis volumes are associated with higher T-cell but not CD34+ doses. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 2, 2018 Category: Hematology Authors: Lisa M. Crisalli, Joanne T. Hinkle, Christopher C. Walling, Mary Sell, Noelle V. Frey, Elizabeth O. Hexner, Alison W. Loren, Selina M. Luger, Edward A. Stadtmauer, David L. Porter, Ran Reshef Source Type: research

Implementing Programmatic Changes Required for New Cellular Therapy Quality Standards and Data Registry Reporting
Background: Although viewed today as novel, the use of chimeric antigen receptor (CAR) T-cell therapy is on the verge of becoming a conventional treatment. Two years ago, the Center for International Blood and Marrow Transplant Research (CIBMTR) issued a request for voluntary reporting of non-hematopoietic cell transplantation (non-HCT) related cellular therapies. Subsequently, the Foundation for the Accreditation of Cellular Therapy (FACT) released new standards requiring programs to implement quality metrics associated with cellular therapy (i.e., immune effector cells). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Claudette G. Edwards, Laurian Walters, Lazaros J. Lekakis, Nathalie Luis, Cara L. Benjamin, Debra Chinquee, Patricia Gomez, Krishna V. Komanduri Source Type: research

Creating a Complex Case Review Committee to Review Psychosocial Barriers to HSCT
While objective physical barriers affecting outcomes for hematopoietic stem cell transplant (HSCT) candidates exist, psychosocial barriers with potential consequences are more subjective and harder to quantify but also important for determining transplant outcomes. Psychosocial barriers may be due to limited social support, constrained resources, and/or impaired coping mechanisms. At our institution, despite obtaining a comprehensive psychosocial evaluation pre-transplant, the approach to management of identified problems varied between providers. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: S. Elizabeth Sharf, Thomas C. Shea, Paul M. Armistead, Kimberly A. Kasow, Maurice Alexander, Deborah Covington, Andrew Sharf, Marcie L. Riches Source Type: research

Quality Rounds: A Multi-Disciplinary Process Improvement Model
Background: In 2015, in preparation for the MUSC Hematopoetic Stem Cell Transplant (HSCT) program's FACT re-accreditation, the MUSC Quality Medical Director, Quality Coordinator, and Nursing Program Manager visited each unit in the Medical Center that treats HSCT patients. The goal of these meetings was to ensure the units were prepared for the upcoming FACT inspection. Often the unit visits led to robust, and surprising discussions regarding opportunities for improvement. Significant changes were implemented after these discussions, increasing communication and education between the units and the HSCT team. (Source: Biolo...
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Elizabeth J. Williams, Michelle Hudspeth, Cindy Kramer Source Type: research

Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant
Despite significant strides in pre-emptive antiviral treatment of cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) and a corresponding reduction in CMV disease rates, toxicity from these therapies remains unacceptably high. New antivirals are urgently needed for CMV management. However, because of low CMV disease rates, clinical trials for new therapeutics and vaccines require large sample sizes to show clinical benefit. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Elizabeth R. Duke, Peter B. Gilbert, Terry L. Stevens-Ayers, Jonathan L. Golob, Nicole Cossrow, Morgan A. Marks, Hong Wan, T. Christopher Mast, Meei-Li W. Huang, Keith R. Jerome, Lawrence Corey, Joshua T. Schiffer, Michael J. Boeckh Source Type: research

Ibrutinib-Mediated Inhibition of cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells
Background: Chronic graft-versus-host disease (cGVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT). Recent studies point to the involvement of T and B cells in the pathogenesis of cGVHD. Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK). In a phase 1b/2 study, ibrutinib showed substantial clinical benefit in patients with cGVHD that had failed frontline therapy (Miklos et  al. ASH 2016). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Bita Sahaf, Dmitry Tebaykin, Melissa Hopper, Patricia Cheung, Fabiola Bittencourt, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Samantha Jaglowski, Jason Lih, Isabelle Solman, Indu D. Lal, Lori Source Type: research

Intestinal Microbiota Injury during Allo-Hct is Generalizable across Transplantation Centers and is Associated with Increased Mortality, Broad-Spectrum Antibiotics, and Decreased Calorie Intake
Intestinal microbiota composition is associated with important outcomes after allo-HCT including survival, relapse, GVHD, and infections. Loss of diversity after allo-HCT and domination by single organisms is common. Low diversity is associated with poor overall survival from transplant-related mortality, including death after GVHD. These observations were all made in single-center cohorts. Here we compare —for the first time—the kinetics of microbiota diversity in allo-HSCT patients (pts) from three independent international institutions. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Jonathan U. Peled, Antonio Gomes, Marissa Lubin Buchan, Christoph Stein-Thoeringer, John Slingerland, Ann E. Slingerland, Daniela Weber, Anthony D. Sung, Molly Maloy, Tatanisha Peets, Boglarka Gyurkocza, Sergio A. Giralt, Robert R. Jenq, Ying Taur, Joao X Source Type: research

Establishing a Standardized System to Capture Chronic GRAFT-Versus-Host Disease (GVHD) DATA in Accordance to the National Institutes of Health (NIH) Consensus Criteria
Background: Ninety percent of patients who develop chronic GVHD (cGVHD) will show symptoms within the first-year post allo-HCT. In order to properly monitor patient outcomes, it is relevant for centers to maintain a systematic approach to collect& accurately document GVHD data through 1 year post allo-HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Djamilia Dierov, Cristi Ciolino, Samira Fatmi, Susan E. Prockop, Miguel-Angel Perales, Doris M. Ponce Source Type: research

Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery
Umbilical cord blood (UCB) transplant has been limited by low number of CD34+ cells, resulting in prolonged periods of cytopenia and high risk of graft failure. MGTA-456, is the UCB product after 15 days in expansion culture with an aryl hydrocarbon receptor (AHR) antagonist in the presence of SCF, Flt-3L, IL-6 and TPO. Based on the safety profile in a prior Phase 1/2 study, we evaluated the effectiveness of MGTA-456 as a stand-alone graft after myeloablative conditioning (MAC) or non-myeloablative conditioning (NMAC). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: John E. Wagner, Claudio G. Brunstein, Todd E. Defor, Anthony E. Boitano, David H. McKenna, Darin Sumstad, Bastiano Sanna, Conrad C. Bleul, Michael Cooke Source Type: research